Publicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (32)

2023

  1. Recommendations for optimizing the use of cytology in the diagnosis and management of patients with lung cancer

    Revista Espanola de Patologia, Vol. 56, Núm. 1, pp. 58-68

2022

  1. Tumor-Intrinsic Nuclear β-Catenin Associates with an Immune Ignorance Phenotype and a Poorer Prognosis in Head and Neck Squamous Cell Carcinomas

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

2021

  1. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

  2. Immune cell infiltrates and neutrophil-to-lymphocyte ratio in relation to response to chemotherapy and prognosis in laryngeal and hypopharyngeal squamous cell carcinomas

    Cancers, Vol. 13, Núm. 9

  3. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era

    European urology oncology, Vol. 4, Núm. 3, pp. 502-505

  4. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2020

  1. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas

    Cancer Immunology, Immunotherapy, Vol. 69, Núm. 10, pp. 2089-2100

2019

  1. The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042

    Journal of Clinical Medicine, Vol. 8, Núm. 8

  2. The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma

    Cancers, Vol. 11, Núm. 11

  3. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2018

  1. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib

    Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905

  2. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781

2015

  1. A labor and cost effective next generation sequencing of PKHD1 in autosomal recessive polycystic kidney disease patients

    Gene, Vol. 561, Núm. 1, pp. 165-169

  2. ABCB1 (MDR-1) pharmacogenetics of tacrolimus in renal transplanted patients: A Next Generation Sequencing approach

    Clinical Chemistry and Laboratory Medicine, Vol. 53, Núm. 10, pp. 1515-1519

  3. Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma

    Oral Diseases, Vol. 21, Núm. 7, pp. 899-904

  4. The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients

    Journal of Human Genetics, Vol. 60, Núm. 5, pp. 273-276

2014

  1. A labor- and cost-effective non-optical semiconductor (Ion Torrent) next-generation sequencing of the SLC12A3 and CLCNKA/B genes in Gitelman's syndrome patients

    Journal of Human Genetics, Vol. 59, Núm. 7, pp. 376-380

  2. Effect of the FTO rs9930506 Polymorphism on the Main Comorbidities of the Cardiorenal Metabolic Syndrome in an Elderly Spanish Cohort

    CardioRenal Medicine, Vol. 4, Núm. 2, pp. 82-87

  3. Farmacogenética del tacrolimus: ¿del laboratorio al paciente?

    Nefrologia, Vol. 34, Núm. 1, pp. 11-17

  4. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1